Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Akili Shifts Strategy to OTC After 46 Staff Laid Off So Far

Akili Shifts Strategy to OTC After 46 Staff Laid Off So Far

16th September 2023

After making 46 people redundant so far in 2023, Akili’s staff cuts are set to continue, focusing on field sales and market access divisions. They expect to have until about 6 months into 2025 before the company’s cash runs out completely.

The majority of Akili’s sales now come from the prescription of EndeavorRx, a video game ADHD therapy that has received FDA approval. An adult version of Endeavor was made available OTC in June. Although this product lacks an FDA designation, Akili published the game as part of a pandemic enforcement policy, which permits businesses to provide individuals with access to this technology before the FDA has given its formal approval.

The company’s Chief Executive Officer, Eddie Martucci, expressed that “our shift to a consumer-led model across our business will maximize our reach in the ADHD patient community and allow us to potentially expand into other large markets, without many of the high cost centers of a prescription model.”

The business had more than 4,000 users in the last 4 months, generating approximately $82 per user throughout that time.

Martucci continued: “A non-prescription model removes reliance on intermediaries, which we believe will give us more control over our growth and enable us to build a lasting, sustainable business.”

The business intends to provide results from clinical trials to the FDA very soon for their adult OTC treatment option, and it intends to present data to the FDA in 2024 for the switch of its pediatric prescription to an OTC medicine.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.